

## News Coverage

Subject

**INTAS launches THYMOTAS -  
a patented, powerful  
immuno-booster add-on to  
standard COVID-19  
treatment**

Publication	Edition	Date	Format
Times of India	Ahmedabad	11/11/2020	Print

# Intas Pharma launches immunity booster to fight coronavirus

## Thymotas Is An Add-On To The Usual Regimen


TIMES NEWS NETWORK

**Ahmedabad:** A pharma major based in Ahmedabad on Tuesday launched a patented research formulation of Thymoquinone that is reported to boost immunity and give greater success in fighting infections.

The formulation has been launched under the name Thymotas by Intas Pharmaceuticals Limited.

"It has been tested clinically as a significant add-on to the standard treatment of Covid-19," Intas said. Thymoquinone is the active biological component of *Nigella sativa*, (popularly known as kalonji, black cumin and kali jeeri).

"Various scientific publications prove Thymoquinone's multiple pharmacologically beneficial pro-



perties," the company said.

According to Intas, the formulation has been developed as a stable, standardized and ready-to-use tablet for the first time in the world.

"Thymotas 12.5mg is very successful in building immunity and combating infections effectively," said Dr Alok Chaturvedi, senior vice-president and head of medical affairs, Intas.

The formulation fights infections through multimodal actions such as anti-viral, anti-bacterial, an-

ti-inflammatory, immuno-modulatory and antioxidant properties.

"Manufactured at a WHO-GMP certified plant, Thymotas is an immunity booster and prophylaxis. One tablet of 12.5mg is recommended daily after meals or as directed by the physician," the company said. The research and development team at Intas has also developed a Covid-19 specific hyperimmune globulin as treatment for patients suffering from moderate to severe Covid-19 infection.

Publication	Edition	Date	Format
Business Standard	Ahmedabad	11/11/2020	Print

## **Intas launches immuno-booster add-on Covid drug**

Drug maker Intas has launched a novel, patented research formulation of Thymoquinone under the brand name of Thymotas for higher success in fighting infection. The firm claims the drug is potential add-on to standard treatment in Covid-19.

**BS REPORTER**

Publication	Edition	Date	Format
JaiH ind	Ahmedabad	11/11/2020	Print

# ઈન્ટાસે રોગપ્રતિકારક શક્તિ વધારતી પેરેન્ટેડ 'થાઈમોટાસ' દવા લોન્ચ કરી

અમદાવાદ તા. ૧૦

ઈન્ટાસે રોગપ્રતિકારક શક્તિ વધારતી, સંક્રમણની સારવારમાં સફળતા આપતી થાઈમોક્વિનોનની પેટન્ટ કરેલી એક નવીનતમ અને સાયન્ટિફિક ફોર્મ્યુલેશન 'થાઈમોટાસ' લોન્ચ કરી છે.

## થાઈમોટાસ કોવિડ-૧૯ ની સારવારમાં સહાયક થશે

થાઈમોટાસનું કોવિડ-૧૯ ની આદર્શ સારવારમાં અસરકારક સહાયક તરીકે તબીબી પરીક્ષણ કરવામાં આવ્યું છે. થાઈમોક્વિનોન (થાઈમોટાસ) નાઈજેલા સટિવા (જેને ક્લોજી અથવા કાળી જીરી તરીકે ઓળખવામાં આવે છે)નું એક્ટિવ બીયો લોજિક કોમ્પોનન્ટ છે. થાઈમોક્વિનોનના ફાયટોકારક ઔષધીય ગુણોની મહત્તને સાબિત કરતા અનેક વૈજ્ઞાનિક પ્રકાશનો ઉપલબ્ધ છે. ઈન્ટાસે વિશ્વમાં પહેલીવાર થાઈમોક્વિનોનને મજબૂત કરે અને સંક્રમણ સામે લડે છે. સાર્સ-સીઓવીટ ની સામે ઈન-વિટ્રો એન્ટિવાઈરલ પરીક્ષણના માધ્યમથી થાઈમોટાસની એન્ટિ-વાઈરલ અસરોને તપાસવામાં આવી છે, રોગપ્રતિકારક શક્તિ વધારવામાં અને સંક્રમણ સામે લડવામાં થાઈમોટાસ ૧૨.૫ મિલિગ્રામ ખુબ જ ઉપયોગી છે.'

આદર્શ સારવારમાં અસરકારક સહાયક તરીકે તબીબી પરીક્ષણ કરવામાં આવ્યું છે. થાઈમોક્વિનોન (થાઈમોટાસ) નાઈજેલા સટિવા (જેને ક્લોજી અથવા કાળી જીરી તરીકે ઓળખવામાં આવે છે)નું એક્ટિવ બીયો લોજિક કોમ્પોનન્ટ છે. થાઈમોક્વિનોનના ફાયટોકારક ઔષધીય ગુણોની મહત્તને સાબિત કરતા અનેક વૈજ્ઞાનિક પ્રકાશનો ઉપલબ્ધ છે. ઈન્ટાસે વિશ્વમાં પહેલીવાર થાઈમોક્વિનોનને

સ્થિર, પ્રમાણભૂત અને રેડી-ટુ-યુઝ ટેબ્લેટ તરીકે વિકસાવી છે. થાઈમોટાસ એન્ટિ-વાઈરલ, એન્ટિ-બેક્ટેરિયલ, એન્ટિ-ઈન્ફલેમેટરી, ઈમ્યુનો-મોડ્યુલેટરી અને એન્ટિઓક્સિડેન્ટ તરીકે વિવિધ રીતે રોગપ્રતિકારક શક્તિને



જે કોવિડ-૧૯ ની આદર્શ સારવારમાં સહાયક દવા તરીકે ઉપયોગ થઈ શકે તેવી પ્રબળ સંભાવના છે.

સિનિયર વાઈસ પ્રેસિડેન્ટ અને મેડિકલ અફેર્સના હેડ ડૉ. આલોક ચતુર્વેદીએ જણાવ્યું હતું કે, 'વર્તમાન મહામારીના સમયમાં

આદર્શ સહાયક દવા તરીકે થાઈમોટાસ ટેબ્લેટનો ભોજન પછી દરરોજ ૫૦ મિલિગ્રામ સુધી ઉપયોગ કરવાની ભલામણ કરવામાં આવે છે. થાઈમોટાસ દવાને આખી જ ગાળવી જોઈએ, તોડવી કે ચાવવી જોઈએ નહીં.

રાયુલાલેનાલેકેલેર,સ્કેશસ્કે,નેો,યેવઈ.લેપરએો.

Publication	Edition	Date	Format
Vadodara Samachar	Vadodara	11/11/2020	Print

પરિણામોની જાહેરાત કરી છે.

માટે ઉપયોગમાં લેવાય છે. નિકાસલક્ષી થઈ.

## ઈન્ટાસફાર્માસ્યૂટિકલ્સરોગપ્રતિકારકશક્તિવધારતી

# પેટેન્ટેડ 'થાઈ મોટાસ' દવા લોન્ચ કરી, જે કોવિડ-૧૯ની સારવારમાં સહાયક થશે

ઈન્ટાસે રોગ પ્રતિકારક શક્તિ વધારતી, સંક્રમણની સારવારમાં સફળતા આપતી થાઈ મોકિવનોન નીપેટન્ટ કરેલી એક નવીનતમ અને સાયન્ટિફિક ફોર્મ્યુલેશન 'થાઈ મોટાસ' લોન્ચ કરી છે. થાઈ મોટાસનું કોવિડ-૧૯ની આદર્શ સારવારમાં અસરકારક સહાયક તરીકે તબીબી પરીક્ષણ કરવામાં આવ્યું છે. થાઈ મોકિવનોન (થાઈમોટાસ) નાઇજેલાસટિવા (જેનેકલોજી અથવા કાળીજીરી તરીકે ઓળખવામાં આવે છે) નું એક્ટિવ બાયોલોજિક કોમ્પોનન્ટ છે. થાઈ મોકિવનોનના ફાયદાકારક ઔષધીય ગુણોની મહત્તાને સાબિત કરતા અનેક વૈજ્ઞાનિક પ્રકાશનો ઉપલબ્ધ છે. ઈન્ટાસે વિશ્વમાં પહેલીવાર થાઈ મોકિવનોનને સ્થિર, પ્રમાણભૂત અને

રેડી-ટુ-યુઝ ટેબ્લેટ તરીકે વિકસાવી છે. થાઈ મોટાસએન્ટિ-વાઈરલ, એન્ટિ-બેક્ટેરિયલ, એન્ટિ-ઈન્ફલેમેટરી, ઈમ્યુનો-મોડ્યુલેટરી અને એન્ટિઓક્સિડેન્ટ તરીકે વિવિધ રીતે રોગપ્રતિકારક શક્તિને મજબૂત કરે અને સંક્રમણ સામે લડે છે. જ્યારે ઈજટરની સામેઈન-વિટ્રોએન્ટિ વાઈરલ પરીક્ષણના માધ્યમથી થાઈ મોટાસની એન્ટિ-વાઈરલ અસરોને તપાસવામાં આવી છે, જે કોવિડ-૧૯ની આદર્શ સારવારમાં સહાયક દવા તરીકે ઉપયોગ થઈ શકે તેવી પ્રબળ સંભાવના છે. સિનિયર વાઈસ પ્રેસિડન્ટ અને મેડિકલ અફેર્સના હેડ ડૉ. આલોક ચતુર્વેદીએ જણાવ્યું હતું કે, "વર્તમાન મહામારીના સમયમાં રોગપ્રતિકારક શક્તિ વધારવામાં અને સંક્રમણ સામે લડવામાં

થાઈ મોટાસ ૧૨.૫ મિલિગ્રામ ખુબજ ઉપયોગી છે. ડબ્લ્યૂ.એચ.ઓ.-જી.એમ.પી.સર્ટિફાઈડ પ્લાન્ટમાં નિર્મિત થાઈમોટાસ રોગપ્રતિકારક શક્તિ વધારવામાં તેમજ સંક્રમણ અટકાવવામાં ઉપચારક તરીકે દરરોજ ભોજન પછી ૧૨.૫ મિલિગ્રામની એક ટેબ્લેટ અથવા ડોક્ટરની સલાહ પ્રમાણે ઉપયોગ કરવાની ભલામણ કરવામાં આવે છે. ડોક્ટરની સલાહ મુજબ અથવા સંક્રમણની ગંભીરતાને ધ્યાનમાં રાખીને સારવારમાં આદર્શ સહાયક દવા તરીકે થાઈ મોટાસ ટેબ્લેટનો ભોજન પછી દરરોજ ૫૦ મિલિગ્રામ સુધી ઉપયોગ કરવાની ભલામણ કરવામાં આવે છે. થાઈ મોટાસ દવાને આખીજ ગળવી જોઈએ, તોડવી કે ચાવવી જોઈએ નહીં.

**પેટાચૂંટણી ૨૦૨૨માં યોજનાર ચૂંટણી પહેલાનું ટ્રેલર છે**

Publication	Edition	Date	Format
Avadh Times	Amreli	11/11/2020	Print

## ઈન્ટાસ ફાર્માસ્યૂટિકલ્સે રોગપ્રતિકારક શક્તિ વધારતી પેટેન્ટેડ 'થાઈમોટાસ' દવા લોન્ચ કરી જે કોવિડ-૧૯ ની સારવારમાં સહાયક થશે



અમદાવાદ, (સાંચેસ ઓનલાઇન) ઈન્ટાસે લેન્ગ્વિનિસારક શક્તિ વધારતી, હંકમણની સારવારમાં સફળતા આપતી થાઈમોક્વિનોનની પેટન્ટ કરેલી એક નવીનતમ અને સાયન્ટિફિક કોમ્પુલેક્શન થાઈમોટાસ લોન્ચ કરી છે. થાઈમોટાસનું ક્રેડિટ ૧૯ ની આદર્શ સારવારમાં અસરકારક સહાયક તરીકે તબીબી પરીક્ષણ કરવામાં આવ્યું છે. થાઈમોક્વિનોન થાઈમોટાસ થાઈમોલા સ્ટિચ (જેને કબોજી અથવા કાળી કાઠી તરીકે સ્વોગળવામાં આવે છે,

એન્ટિબાયોટિક્સ કોમ્બોનન્ટ છે. થાઈમોક્વિનોનના સંપર્કકારક એપીલેવ ગુણોની ઘટ્ટતાને સાબિત કરતા

અનેક વેલોનીક પ્રકારનો ઉપવર્ગ છે. ઈન્ટાસે વિશ્વમાં પહેલીવાર થાઈમોક્વિનોનનો સ્થિર, પ્રખ્યાતમુખ અને રેડી દુ પુલ ટેબ્લેટ તરીકે વિશ્લેષણ કર્યું છે. થાઈમોટાસ એન્ટિ થાઈરોક્સ, એન્ટિ બેક્ટેરિયલ, એન્ટિ ઈન્ફલેમેટરી, ઈમ્યુનો મોડ્યુલેટરી અને એન્ટિ ઓક્સિડેન્ટ તરીકે વિવિધ રીતે રોગપ્રતિકારક શક્તિને મજબૂત કરે અને સંક્રમણ સાથે લડે છે. એસએસઆરએસ સીન્ડ્રોમી વ ની સામે ઈન વિટ્રો એન્ટિથાઈરોક્સ પરીક્ષણના મતલબથી થાઈમોટાસની એન્ટિ થાઈરોક્સ અસરોને તપાસવામાં આવી છે, જે કોવિડ ૧૯ ની આદર્શ સારવારમાં સહાયક દવા તરીકે ઉપયોગ થઈ શકે તેવી પ્રબળ સંભાવના છે, જાણ માહિતી માટે [www.thymotas.com](http://www.thymotas.com) ની મુલાકાત લો.

Publication	Edition	Date	Format
Rajasthan Patrika	Jaipur	11/11/2020	Print

संशोधन एवं प्रौद्योगिकी विभाग, दिल्ली

## इंटास ने लॉन्च की थाइमोटास

नई दिल्ली. इंटास फार्मा ने ने रोग प्रतिरोधक शक्ति बढ़ाने और संक्रमण के उपचार में सफलता सुनिश्चित करने वाली थाइमोक्विनोन की एक नवीनतम और सायन्टिफिक संशोधात्मक रचना थाइमोटास लॉन्च की है। थाइमोटास एंटी वायरल, एंटी बैक्टीरियल, एंटी इंप्लेमेंटरी के तौर पर रोग प्रतिरोधक शक्ति को मजबूत करता है। यह सिनियर वाइस प्रेसिडेंट आलोक चतुर्वेदी ने दी।

Publication	Edition	Date	Format
Dainik Aaj	Agra	11/11/2020	Print

धे।  
 प्रतिरोधक क्षमता बढ़ाने में सहायक  
 आगता। इन्डास ने रोग  
 प्रतिरोधक शक्ति बढ़ाने वाली  
 और संक्रमण के उपचार में  
 सफलता सुनिश्चित करने वाली,  
 थाइमोक्विनोन की एक  
 नवीनतम और सार्वान्तरिक  
 एंथिम्योजेन संशोधात्मक रचना  
 प्रथाइमोटासह्लॉन्च की  
 है। थाइमोटास कोविड-19 के  
 मानक उपचार में अस्सरकारक  
 सहायक के तौर पर नैदानिक  
 रूप से परीक्षण किया  
 गया। सिनिवर वाइस प्रेसिडेंट  
 और मेडिकल अफेयर्स के हेड  
 डॉ. आलोक चतुर्वेदी ने कहा  
 कि, ह्वर्तमान महामारी के  
 समय में रोग प्रतिरोधक शक्ति  
 को बढ़ाने और संक्रमण के  
 सामने लड़ने के लिए  
 थाइमोटास 12.5 मिलिग्राम  
 प्रभावी रूप से बहुत उपयोगी  
 है। डब्ल्यू.एच.ओ.-  
 जी.एम.पी. सर्टिफाइड प्लान्ट  
 में निर्मित थाइमोटास रोग  
 प्रतिरोधक शक्ति को बढ़ाने एवं  
 संक्रमण रोकने में उपचारक के  
 तौर पर हर रोज भोजन के बाद  
 12.5 मिलिग्राम की एक  
 टैब्लेट या डॉक्टर से परामर्श  
 अनुसार प्रयोग करने की  
 सिफारिश की जाती है।



Publication	Edition	Date	Format
Amar Bharti	Agra	11/11/2020	Print

## कोविड-19 के उपचार में सहायक होगी पैटन्टड 'थाइमोटास'

नई दिल्ली। इन्टास ने रोग प्रतिरोधक शक्ति बढ़ाने वाली और संक्रमण के उपचार में सफलता सुनिश्चित करने वाली थाइमोक्विनोन की एक नवीनतम और सायन्टिफिक फॉर्म्यूलेशन संशोधात्मक रचना 'थाइमोटास' लॉन्च की है। थाइमोटास कोविड-19 के मानक उपचार में असरकारक सहायक के तौर पर नैदानिक रूप से परीक्षण किया गया है। थाइमोक्विनोन नाइजेला सटिवा (जिसको कलौंजी एवं काली जीरी के नाम से भी जाना जाता है) के एक्टिव बायोलॉजिकल कोम्पोनन्ट है। थाइमोक्विनोन के लाभकारी औषधीय गुणों साबित करने के लिए विभिन्न वैज्ञानिक प्रकाशन उपलब्ध है। विश्व में पहलीबार थाइमोक्विनोन को स्थिर, मानकीकृत और रेडी-टु-युज टैब्लट के रूप में विकसित किया गया है।

Publication	Edition	Date	Format
Everyday News	Lucknow	11/11/2020	Print

## इन्टास फार्मास्यूटिकल्स ने रोग प्रतिरोधक शक्ति बढ़ाने वाली पैटन्टड 'थाइमोटॉस' दवाई लॉन्च की, जो कोविड-19 के उपचार में सहायक होगी

### एबरीडे न्यूज संवाददाता

इन्टास ने रोग प्रतिरोधक शक्ति बढ़ाने वाली और संक्रमण के उपचार में सफलता सुनिश्चित करने वाली थाइमोक्विनोन की एक नवीनतम और सांख्यिकीय फर्मेयूनेशन संशोधनात्मक रचना 'थाइमोटॉस' लॉन्च की है। थाइमोटॉस कोविड-19 के मानक उपचार में अत्यधिक सहायक के तौर पर वैद्यनिक रूप से परीक्षण किया गया है। थाइमोक्विनोन (थाइमोटॉस) जाड़ेला सटिका (जिस्को कलौजी एवं काली जीरी के पत्र से भी जाना जाता है) के एक्टिव बायोलॉजिकल कोम्पौनंट है। थाइमोक्विनोन के लाभकारी औषधीय गुणों साबित करने के लिए विभिन्न वैज्ञानिक प्रकाशन उपलब्ध है। इन्टास द्वारा विश्व में पहलीबार थाइमोक्विनोन को स्मिथ, मानकोकृत और टेटी-टु-युज टैब्लेट के रूप में विकसित किया गया है। थाइमोटॉस एंटी-कपरल, एंटी-बैक्टीरियल, एंटी-इंफ्लेमेटरी, इम्यूनोमॉड्यूलेटरी और एंटीऑक्सिडेंट के तौर पर रोग प्रतिरोधक शक्ति को मजबूत करता है और संक्रमण से लड़ता है। इन्फ्लूएंजा के सामने इन-विट्रो एंटीवायरल परिधन के माध्यम से थाइमोटॉस के एंटी वायरल प्रभाव की जांच कि गई है, जिसमें कोविड-19 के मानक उपचार में



सहायक दवाई के तौर पर प्रयोग को ज़रूरत संभावना है। सिनिपर वाइस प्रेसिडेंट और मेडिकल अफेयर्स के हेड डॉ. अशोक चतुर्वेदी ने कहा कि, वर्तमान महामारी के समय में रोग प्रतिरोधक शक्ति को बढ़ाने और संक्रमण के सामने लड़ने के लिए थाइमोटॉस 12.5 मिलिग्राम प्रभावी रूप से बहुत उपयोगी है डबल्यू.एच.ओ.-जी.एम.पी. सर्टिफाइड प्लान्ट में निर्मित थाइमोटॉस रोग प्रतिरोधक शक्ति को बढ़ाने एवं संक्रमण रोकने में उपचारक के तौर पर हर रोज़ भोजन के बाद 12.5 मिलिग्राम को एक टैब्लेट या डॉक्टर से परामर्श अनुसार प्रयोग करने की सिफारिश की जाती है। डॉक्टर के परामर्श अनुसार या संक्रमण की तीव्रता के अनुसार मानक सहायक दवाई के तौर पर थाइमोटॉस टैब्लेट की भोजन के बाद हर रोज़ 50 मिलिग्राम तक प्रयोग करने की सिफारिश की जाती है।

## Online Coverage

Subject

**INTAS launches THYMOTAS -  
a patented, powerful  
immuno-booster add-on to  
standard COVID-19  
treatment**

Publication	Edition	Date	Format
Times of India	Online	11-11-2020	Digital

WED, NOV 11, 2020 | UPDATED 11:56AM IST

# THE TIMES OF INDIA

SEARCH

[Home](#)
[Briefs](#)
[TOI](#)
[Videos](#)
[City](#)
[India](#)
[Elections](#)
[World](#)
[Business](#)
[Tech](#)
[Cricket](#)
[IPL](#)

NEWS > INTAS

## Intas Pharma launches immunity booster to fight coronavirus

TNN Nov 11, 2020 06:03:07



**Associated:** A pharma major based in Ahmedabad on Tuesday launched a patented research formulation of Thymoquinone that is reported to boost immunity and give greater success in fighting infections.

The formulation has been launched under the name Thymotax by Intas Pharmaceuticals Limited.

**Click Cover Story**

**Do copy paste work and earn upto Rs.1000/day from home!**

**INDIA MORE**



Advertisement by [adsterra](#)

"It has been tested clinically as a significant add-on to the standard treatment of Covid-19," Intas said. Thymoquinone is the active biological component of *Nigella arava*, popularly known as kalonji, black cumin and kalajira.

"Various scientific publications prove Thymoquinone's multiple pharmacologically beneficial properties," the company said.

Publication	Edition	Date	Format
India Today	India	10/11/2020	Digital

[NEWS](#)[• LIVE TV](#)**INDIA  
TODAY**[APP](#)[MAGAZINE](#)[POLITICS](#)[ELECTIONS](#)[ELECTION DASHBOARD](#)[MALAYALAM](#)[IPL 2020](#)[CORONA](#)[AIR QUALITY](#)[VIDEOS](#)[...](#)

ADVERTISEMENT

# INTAS launches THYMOTAS – a patented powerful immuno-booster add-on to standard COVID-19 treatment

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ – Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
Business Line	Online	10/11/2020	Digital

**BusinessLine** THE BUSINESS LINE

iPhone 12 Pro Max | ₹5,000 Cashback on HDFC Bank Cards and EasyEMI\*

HOME NEWS MARKETS COMPANIES ECONOMY INFO-TECH OPINION SPECIALS PORTFOLIO PREMIUM MORE- Q Search

LATEST NEWS | PORTFOLIO | ECONOMY | B.L ON CAMPUS | MONEY & BANKING | CARTOONS | RESOURCES | MSME | KNOWLEDGE SERIES (VIDEOS) | VISUALDLY

**Science**

# Intas launches Thymotas as adjunct to Covid treatment

Our Bureau | Ahmedabad | Updated on November 10, 2020 | Published on November 10, 2020



Thymoquinone, an active biological component of black cumin,

fortifies immunity against infection

Pharma player Intas Pharmaceuticals Limited on Tuesday launched a novel patented formulation of Thymoquinone under the name of Thymotas towards Covid-19 treatment.

The company said Thymotas has been tested clinically as a significant add-on or an adjunct to infection treatment for standard Covid-19 cure.

Thymoquinone (Thymotas), which fortifies immunity and ensures higher success in fighting infection, is the active biological component of Nigella Sativa, (popularly known as kalonji, black cumin, kali jeeri).

Honey and Nigella Sativa help in COVID-19 viral clearance and reduce severity: Study

In response to *BusinessLine's* query, Dr Alok Chaturvedi, Senior Vice President & Head - Medical Affairs, said, "Black cumin/kalaunji having thymoquinone as its main bioactive component has been used for centuries as traditional medicine. It has been documented to have antiviral effect besides antibacterial, immunomodulatory, anti-inflammatory and antioxidant actions."

"As per the published data its proposed mechanism of action is multimodal e.g. preventing entry as well as replication of virus inside the cell. In the in-vitro study its antiviral effect has been validated," he added.

## Ready-to-use tablet

Thymoquinone has been developed as a stable, standardised and ready-to-use tablet by Intas. The company claims it to be the first in the world.

Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in Covid-19.

In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively, Chaturvedi said, adding that Thymotas is recommended for prevention and also as an add-on to standard Covid treatment.

Manufactured at the company's WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. The company looks to target the market segments of immunity boosters for prevention and supportive therapy market to the existing standard Covid treatment.

Publication	Edition	Date	Format
THE WEEK	Online	10/11/2020	Digital

# INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

PTI | November 10, 2020 15:59 IST

(Eds: Disclaimer: The following press release comes to you under an arrangement with PRNewswire. PTI takes no editorial responsibility for the same.)

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ – Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
Business Today	Online	10/11/2020	Digital

# Business Today

Tuesday, November 10, 2020 | Updated 19:07 IST

## INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.



Publication	Edition	Date	Format
Divya Bhaskar	Gujarat	10/11/2020	Digital

**દિવ્ય ભાસ્કર**

હોમ

વીડિ

ટાપ ન્યૂઝ

મારું શહેર

બિહાર ઇલેક્શન

IPL 2020

મારું ગુજરાત

ઓરિજિનલ

મેગેઝિન

ઈન્ડિયા

વર્લ્ડ

એન્ટરટેઇનમેન્ટ

કોરોનાવાયરસ

રાશિક્ષણ

સ્પાટ્સ

Download App from



Follow us on



Corona Treatment

## કોવિડ-19: ઈન્ટાસ ફાર્માસ્યૂટિકલ્સે કોરોના સારવારમાં ઉપયોગી રોગપ્રતિકારક શક્તિ વધારતી પેટેન્ટેડ થાઈમોટાસ દવા લોન્ચ કરી

અમદાવાદ અમુક પળો પહેલા



- થાઈમોક્વિનોનને રેડી-ટુ-યુઝ ટેબ્લેટ તરીકે વિકસાવનાર ઈન્ટાસ વિશ્વની પહેલી કંપની

ગુજરાતની અગ્રણી ફાર્મા કંપની ઈન્ટાસે રોગપ્રતિકારક શક્તિ વધારતી, સંક્રમણની સારવારમાં સફળતા આપતી થાઈમોક્વિનોનની પેટન્ટ કરેલી એક નવીનતમ અને સાયન્ટિફિક ફોર્મ્યુલેશન 'થાઈમોટાસ' લોન્ચ કરી છે. થાઈમોટાસનું કોવિડ-19ની આદર્શ સારવારમાં અસરકારક સહાયક તરીકે તબીબી પરીક્ષણ કરવામાં આવ્યું છે. સિનિયર વાઈસ પ્રેસિડન્ટ અને મેડિકલ અડ્વર્સના હેડ આલોક ચતુર્વેદીએ જણાવ્યું હતું કે, વર્તમાન મહામારીના સમયમાં રોગપ્રતિકારક શક્તિ વધારવામાં અને સંક્રમણ સામે લડવામાં થાઈમોટાસ 12.5 મિલિગ્રામ ખુબ જ ઉપયોગી સાબિત થશે.

### વિશ્વની પહેલી થાઈમોક્વિનોન ટેબ્લેટ બનાવી

થાઈમોક્વિનોન (થાઈમોટાસ) નાઇજેલા સટિવા (જેને કલોજી અથવા કાળી જીરી તરીકે ઓળખવામાં આવે છે)નું એક્ટિવ બાયોલોજિક કોમ્પોનન્ટ છે. થાઈમોક્વિનોનના ફાયદાકારક ઔષધીય ગુણોની મહત્તાને સાબિત કરતા અનેક વૈજ્ઞાનિક પ્રકાશનો ઉપલબ્ધ છે. ઈન્ટાસે વિશ્વમાં પહેલીવાર થાઈમોક્વિનોનને સ્થિર, પ્રમાણભૂત અને રેડી-ટુ-યુઝ ટેબ્લેટ તરીકે વિકસાવી છે.

### એન્ટિ-વાઈરલ અસરોને તપાસવામાં આવી છે

કંપનીએ જણાવ્યું હતું કે, થાઈમોટાસ એન્ટિ-વાઈરલ, એન્ટિ-બેક્ટેરિયલ, એન્ટિ-ઈન્ફલેમેટરી, ઈમ્યુનો-મોડ્યુલેટરી અને એન્ટિ-ઓક્સિડન્ટ તરીકે વિવિધ રીતે રોગપ્રતિકારક શક્તિને મજબૂત કરે અને સંક્રમણ સામે લડે છે. SARS-CoV2ની સામે ઇન-વિટ્રો એન્ટિવાઈરલ પરીક્ષણના માધ્યમથી થાઈમોટાસની એન્ટિ-વાઈરલ અસરોને તપાસવામાં આવી છે, જે કોવિડ-19ની આદર્શ સારવારમાં સહાયક દવા તરીકે ઉપયોગ થઈ શકે તેવી પ્રબળ સંભાવના છે. થાઈમોટાસ રોગપ્રતિકારક શક્તિ વધારવામાં તેમજ સંક્રમણ અટકાવવામાં ઉપચારક તરીકે દરરોજ ભોજન પછી 12.5 મિલિગ્રામની એક ટેબ્લેટ અથવા ડોક્ટરની સલાહ પ્રમાણે ઉપયોગ કરવાની ભલામણ કરવામાં આવે છે.



## INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

**Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs**, said: *"In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."*

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
Telangana Today	Online	10/11/2020	Digital

# Telangana Today

Tuesday, November 10, 2020

[Home](#) | [Hyderabad](#) | [Telangana](#) | [Andhra Pradesh](#) | [India](#) | [World](#)

## **INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment**

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ – Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.


Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
SOCIALNEWS.XYZ	Online	10/11/2020	Digital

**SOCIALNEWS.XYZ**  
*The Millennial Media*



Home Politics Movies Gallery Videos Business Sports Science/Tech Study

## PR Newswire



**CISION**

INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
Sambad English	Online	10/11/2020	Digital



## INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
One News Page	Online	10/11/2020	Digital

One News Page  
Trusted News Discovery Since 2008

# INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
CISION	Online	10/11/2020	Digital



## INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

NEWS PROVIDED BY  
**Intas Pharmaceuticals Ltd** →  
10 Nov, 2020, 15:29 IST

SHARE THIS ARTICLE



AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
UDISHA BYTES	Online	10/11/2020	Digital



## **INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment**

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.



Publication	Edition	Date	Format
PNN	Online	10/11/2020	Digital



## Health

# INTAS launches THYMOTAS – a patented powerful immuno-booster add-on to standard COVID-19 treatment

📅 November 10, 2020 👤 JMR 💬 0 Comments 🔍 booster, immuno, intas, launches, patented, powerful, thymotas

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ — Intas announces the launch of Thymotas – a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeer)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
DALAL STREET INVESTJOURNAL	Online	10/11/2020	Digital



---

## INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

---

Publication	Edition	Date	Format
DKODIG	Online	10/11/2020	Digital



## INTAS launches THYMOTAS – a patented powerful immuno-booster add-on to standard COVID-19 treatment

DKODING - 10 11 2020 04:00 PM



AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ — Intas announces the launch of Thymotas – a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
	Online	10/11/2020	Digital



# INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
Mangalorean	Online	10/11/2020	Digital

## **Mangalorean** Fighting Ignorance, Since 2003

# INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
UPDATE ODISHA	Online	10/11/2020	Digital

# UPDATE ODISHA

## **CISIONINTAS** launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.

Publication	Edition	Date	Format
NRI NEWS 24x7	Online	10/11/2020	Digital



## INTAS launches THYMOTAS - a patented powerful immuno-booster add-on to standard COVID-19 treatment

AHMEDABAD, India, Nov. 10, 2020 /PRNewswire/ -- Intas announces the launch of Thymotas - a novel, patented research formulation of Thymoquinone that fortifies immunity and ensures higher success in fighting infection. Thymotas has been tested clinically as a significant add-on to the standard COVID-19 treatment.

Thymoquinone (Thymotas) is the active biological component of *Nigella sativa*, [also known as Kalonji, Black Cumin (Kali Jeeri)]. There are various scientific publications available that prove Thymoquinone's multiple pharmacologically beneficial properties. Thymoquinone has been developed as a stable, standardized and ready-to-use tablet by Intas for the first time in the world.

Thymotas fortifies immunity and fights infections through multimodal actions such as Anti-viral, Anti-bacterial, Anti-inflammatory, Immuno-modulatory and Antioxidant. Thymotas' anti-viral effects have been demonstrated via an in-vitro test against SARS-CoV2 and has tremendous potential as a potent add-on to the standard treatment in COVID-19.

Dr Alok Chaturvedi, Senior Vice-President & Head-Medical Affairs, said: "In the current pandemic, Thymotas 12.5 mg is very successful in building immunity and combating infections effectively."

Manufactured in a WHO-GMP certified plant, Thymotas as an immunity booster & prophylaxis is recommended one tablet of 12.5 mg daily after meals or as directed by the physician. As an adjunct to infection treatment, Thymotas is recommended up to 50 mg per day after meals based on the severity of infection or as directed by the physician. Thymotas is to be swallowed as a whole and not to be crushed or chewed.